Home / Companies / Revance Therapeutics, Inc. / 1 May 2024
Revance Therapeutics, Inc.: meeting of 1 May 2024
Votes reported on Form N-PX, item by item
266 Form N-PX filers reported votes at the Revance Therapeutics, Inc. meeting of 1 May 2024. Their records fall into 3 items below, in ballot order: management items first, then proposals from security holders. Each bar shows how the reporting filers split; it is not the result of the meeting.
foragainstabstain, withhold or otheramber tick: the portion cast against management
Items
DIRECTOR ELECTIONSIssuer
Director elections
3 nominees; 77.0% of reported votes for; 30 filers withheld from or voted against at least one nominee.
402 vote records from 83 filers. 22 of the 83 filers that marked the item either way voted against management.
SECTION 14A SAY-ON-PAY VOTESIssuer
Advisory vote on executive pay (say-on-pay)
354 vote records from 263 filers. 69 of the 249 filers that marked the item either way voted against management. 14 filers reported this item without a management mark.
AUDIT-RELATEDIssuer
Audit-related items (auditor ratification)
134 vote records from 83 filers. 1 of the 83 filers that marked the item either way voted against management.
How the largest families voted
| Family | 1. Directors | 2. Say-on-pay | 3. Auditor |
|---|---|---|---|
| Vanguard | For | For | For |
| BlackRock and iShares | For | For | For |
| Fidelity | For | For | For |
| Dimensional | No report | Against * | No report |
| State Street and SPDR | For | For | For |
| Franklin Templeton | For | Against * | For |
| Invesco | For | For | For |
| Equitable | For | For | For |
| Charles Schwab | For | For | For |
| Nuveen and TIAA | For | For | For |
| ProShares and ProFunds | Abstain or withhold * | For | For |
| John Hancock and Manulife | Abstain or withhold * | For | For |
| Morgan Stanley, Eaton Vance and Calvert | For | For | For |
| J.P. Morgan | For | Against * | For |
| Goldman Sachs | No report | For | No report |
| PGIM and Prudential | No report | Against * | No report |
| Jackson National funds | Abstain or withhold * | Against * | For |
| Northern Trust and FlexShares | For | For | For |
| SEI | For | Against * | For |
| T. Rowe Price | For | For | For |
| Lincoln Financial | For | For | For |
| Voya | For | Against * | For |
| Nationwide | For | Against * | For |
| Victory Capital | Abstain or withhold * | For | For |
| Brighthouse Funds | Abstain or withhold * | For | For |
| Guggenheim and Rydex | Abstain or withhold * | For | For |
| Columbia Threadneedle | For | For | For |
| BNY Mellon | Abstain or withhold * | For | For |
| Principal | Abstain or withhold * | For | For |
| Capital Group and American Funds | For | For | For |
| Pacific Life funds | For | For | For |
| Global X | For | Against * | For |
| Federated Hermes | For | For | For |
| AllianceBernstein | No report | For | No report |
| DWS | Abstain or withhold * | For | For |
| Janus Henderson | No report | For | No report |
| Neuberger Berman | No report | Against * | No report |
| Baird | No report | For | No report |
* against management. A family's position is the way most of its reported shares were voted across its filers; "split" means no single position led. "No report" means none of the family's filers listed the item.
Questions
How did large funds vote at the Revance Therapeutics, Inc. meeting?
266 Form N-PX filers reported votes at the meeting of 1 May 2024. On say-on-pay, 69 of 249 voted against management (27.7%). The family table lists each of the largest families item by item.
Is this the meeting result?
No. These are the votes of funds and managers that file Form N-PX, counted by filer and by the shares they reported. The certified result, which includes every shareholder, is reported by Revance Therapeutics, Inc. on Form 8-K.
Why are director elections shown as counts only?
Director records name the nominee. This site does not publish pages or rows about individuals, so for director elections it keeps the number of nominees and the split of votes and discards the wording.
Every meeting on file for Revance Therapeutics, Inc.
Provenance: SEC EDGAR, Form N-PX and N-PX/A filings listing Revance Therapeutics, Inc. with a meeting date within three days of 1 May 2024. Proposal titles are the most common wording among filers and are replaced by the SEC category where a wording could name a person. Not verified by the SEC. Filings read through 30 Sep 2026.